A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) versus Best Available Therapy (BAT) in Participants with Essential Thrombocythemia who have an Inadequate Response to or are Intolerant of Hydroxyurea.